✓ Having a shared terminology and ontology for nocturnal scratch facilitated conversation between Sibel, the FDA, pharmaceutical companies, and other stakeholders by ensuring that everyone had the same baseline understanding of the concept.

✓ Inputs from the patient study were critical in determining the outcome measure that would be most valuable to patients in drug development of the final version of the endpoint.